Jagpal Sukhi 4

What Happened Jagpal Sukhi, a director of Sutro Biopharma, was granted a derivative award covering 10,000 shares on June 5, 2026. The reported acquisition price is $0.00, meaning no cash was paid for the award at grant. This is a compensation-type grant (not an open-market purchase or sale) and does not represent an immediate sale or purchase of common shares.

Key Details

• Transaction date: 2026-06-05; Form 4 filed 2026-06-09 (no late filing flag indicated).
• Transaction type/code: A (grant/award — derivative securities).
• Shares/units granted: 10,000 (reported acquisition price $0.00).
• Shares owned after transaction: Not specified in the provided filing.
• Footnote (vesting): Award vests monthly at 8.33% of the total each month, first tranche vests July 5, 2026; fully vested on the earlier of the issuer’s 2027 annual meeting or June 5, 2027.

Context This grant is a time‑based derivative award (likely options or RSUs as reported on the Form 4) that vests over roughly one year; it does not indicate immediate share ownership or a cash market transaction. Grants to directors are common as compensation and should be interpreted differently from open‑market purchases, which are generally a clearer bullish signal.